Patent ID: 8178092
Filing Date: 2012-05-15
Classification: A61K,A61P,C07K,Y10S

Abstract:
1. A method of treating psoriasis in a subject comprising administering to the subject an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, for a first extended period of at least 12 weeks, wherein the subject achieves at least a Psoriasis Area and Severity Index (PASI) 75 response by week 12 of the first extended period, discontinuing administration of the antibody, or antigen-binding portion thereof, for at least 12 weeks following the first extended period of administration of the antibody, or antigen-binding portion thereof, wherein the subject exhibits a loss of response by a decrease in PASI score to less than PASI 50 following discontinuation, and re-administering to the subject the antibody, or antigen-binding portion thereof, for a second extended period of at least 12 weeks, wherein the subject achieves at least a PASI 50 response by week 12 of the second extended period, thereby treating psoriasis in the subject.